GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Capex-to-Operating-Income

Oculis Holding AG (FRA:CR5) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Oculis Holding AG's Capital Expenditure for the three months ended in Mar. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-15.87 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Oculis Holding AG Capex-to-Operating-Income Historical Data

The historical data trend for Oculis Holding AG's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Capex-to-Operating-Income Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
- - - -

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oculis Holding AG's Capex-to-Operating-Income

For the Biotechnology subindustry, Oculis Holding AG's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oculis Holding AG's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's Capex-to-Operating-Income falls into.



Oculis Holding AG Capex-to-Operating-Income Calculation

Oculis Holding AG's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.051) / -48.619
=N/A

Oculis Holding AG's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -15.87
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oculis Holding AG  (FRA:CR5) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Oculis Holding AG Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Oculis Holding AG (FRA:CR5) Business Description

Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines